Fast Five Quiz: Treatment of Chronic Migraine

Jasvinder P. Chawla, MD, MBA 


March 07, 2022

Menstrual migraine affects up to 25% of female migraineurs in the general population and 22%-70% of patients who present to headache clinics. In women diagnosed with menstrual migraine, perimenstrual migraines are associated with considerably greater disability than their non-menstrual attacks. Patients with chronic migraine who are receiving preventive therapy and experiencing breakthrough menstrual migraine headaches may benefit from perimenstrual elevation of the dose of the preventive medication.

Short-term, perimenstrual use of preventive agents (eg, frovatriptan) can be beneficial for patients with chronic and severe menstrual migraine. In patients who do not respond to standard preventive measures, hormonal therapy may be beneficial. Options include estrogen supplementation with a transdermal patch or oral contraceptives.

Learn more about migraine variants.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.